|
2,5-bis-O-{3-[amino(imino)methyl]phenyl}-1,4_3,6-dianhydro-D-glucitol
|
DB04790 |
|
|
Phytosphingosine
|
DB14119 |
|
|
Setogepram
|
DB15447 |
[Setogepram is under investigation in clinical trial NCT03184584 (Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome).] |
|
Silodrate
|
DB14116 |
|
|
Human botulinum neurotoxin A/B immune globulin
|
DB14115 |
|
|
Vidofludimus
|
DB15446 |
[Vidofludimus is under investigation in clinical trial NCT03722576 (Vidofludimus Calcium for Primary Sclerosing Cholangitis).] |
|
Citarinostat
|
DB15449 |
[Citarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM).] |
|
Silica dimethyl silylate
|
DB14117 |
|
|
Acumapimod
|
DB15448 |
[Acumapimod is under investigation in clinical trial NCT02926326 (The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers).] |
|
Human vaccinia virus immune globulin
|
DB14112 |
[Human vaccinia immune globulin (VIG) is a sterile solution containing the purified gamma globulin (IgG) fraction of plasma taken from healthy donors previously vaccinated with live vaccinia virus vaccine who possess high titers of anti-vaccinia virus antibody [FDA Label, A33814]. The IgG fraction is purified by the anion-exchange column chromatography method and the solution is solvent/detergent-treated to sterilize the compound [A33814]. Most compounds used currently are intravenous formulations, which contain no preservatives - unlike prior intramuscular compounds which contained thiomersal, a mercury derivative preservative that could be potentially teratogenic [A33814].
Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with its availability and effectiveness [A33798, A33814].] |
|
Lorukafusp alfa
|
DB15443 |
[Lorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).] |
|
Trilaciclib
|
DB15442 |
[Trilaciclib is under investigation in clinical trial NCT02514447 (Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy).] |
|
Ceramide NP
|
DB14111 |
[Ceramide NP is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin. Ceramide 3 consists of a phytosphingosine backbone N-acylated with a saturated fatty acid (stearic acid) [A27233]. It is widely used as a moisturizer in various cosmetic and personal products. Together with ceramide 1, they synergistically improve the skin barrier function in humans [A27232, A27233].] |
|
Viper antivenom
|
DB14114 |
|
|
Iodohippuric acid
|
DB15445 |
[Iodohippuric acid is under investigation in clinical trial NCT02599844 (Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults).] |
|
Elexacaftor
|
DB15444 |
[Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.[A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>.[L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor.[A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for the _F508del-CFTR_ gene.[A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or produces proteins unresponsive to ivacaftor or tezacaftor.[A187361] The triple combination product Trikafta<sup>TM</sup>, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous for the _F508del-CFTR_ gene - this represents approximately 70[A187373]-90%[A187361,A187355] of all CF patients.] |
|
Black widow spider antivenin (equine)
|
DB14113 |
|
|
Lulizumab pegol
|
DB15441 |
[Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).] |
|
Butylene glycol
|
DB14110 |
|
|
GSK-3117391
|
DB15440 |
[GSK-3117391 is under investigation in clinical trial NCT02965599 (Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis).] |
